Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8996137 | 1.00 | L3MBTL1 (0.49) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL3264038 | 1.00 | L3MBTL1 (0.49) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL3263015 | 0.84 | HTT (0.47) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL3263011 | 0.84 | HTT (0.47) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL8996243 | 0.84 | HTT (0.47) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL8996235 | 0.83 | HTT (0.38) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL8996290 | 0.83 | HTT (0.38) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL8996387 | 0.82 | L3MBTL1 (0.41) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL8996383 | 0.82 | L3MBTL1 (0.41) | L3MBTL1MAPTMEN1KMT2AHTT | |
| SCHEMBL14969758 | 0.81 | MEN1 (0.39) | L3MBTL1MAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594843-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative | TAKASAGO PERFUMERY CO LTD (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7601842-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060122225-A1 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | L3MBTL1 4666/4885MAPT 4178/4885MEN1 1376/4885 |
| US-20060122225-A1 | Method for producing an optically active tetrahydroquinoline | AADAT, KMO, ALDH7A1 | L3MBTL1 4666/4885MAPT 4178/4885MEN1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.